To register CAGR Of 6.6%: Global In-vitro Diagnostics Instruments Market about to hit CAGR of 6.6% from 2017 to 2026
The global in-vitro diagnostics instruments market was valued at US$ 7,316.9 Mn in 2016 and is projected to reach US$ 13,881.5 Mn in 2026 at a CAGR of 6.6% from 2017 to 2026. The immunochemistry segment in the global In-vitro diagnostics instruments market is estimated to account for major revenue share of 25.3% in 2017, owing to factors such as increasing cases of hypo, hyperthyroidism, cardiovascular diseases and oncology cases, and increasing expenditure on research & development to develop and introduce more advanced in-vitro diagnostics instruments.
Global In-Vitro Diagnostic Instruments Market: Segmental Snapshot
By product type: Immunochemistry segment is estimated to register a CAGR of over 7.7%, thereby accounting for highest revenue share among the type segments.
By end user: Hospitals and diagnostic laboratories segment is estimated to account for highest revenue share among the application segments, registering a CAGR of over 7.3% over the forecast period.
By region: The market in North America accounted for highest revenue share in the global in vitro diagnostic instruments market in 2016, and is expected to record CAGR of over 6.6% between 2016 and 2026.
Global In-Vitro Diagnostic Instruments Market: Competitive Analysis
The global in-vitro diagnostic instruments market includes detailed competitive analysis on major companies such as Abbott, Danaher, F. Hoffmann-La Roche Ltd., bioMérieux SA, Thermo Fisher Scientific Inc., Alere Inc., Becton, Dickinson and Co., Siemens AG, and Sysmex Corporation.